Premium
(‐)‐Epigallocatechin Gallate Inhibits Endothelin‐1‐Induced C‐Reactive Protein Production in Vascular Smooth Muscle Cells
Author(s) -
Wang ChenJing,
Liu JunTian,
Guo Fang
Publication year - 2010
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2010.00557.x
Subject(s) - epigallocatechin gallate , vascular smooth muscle , gallate , endothelin 1 , chemistry , endothelin receptor , smooth muscle , pharmacology , microbiology and biotechnology , medicine , endocrinology , biochemistry , biology , polyphenol , receptor , antioxidant
Numerous studies have shown that C‐reactive protein (CRP), a pro‐inflammation cytokine, makes a direct contribution to atherosclerosis, and that (–)‐epigallocatechin gallate (EGCG) is able to exert an anti‐atherosclerotic effect by anti‐oxidative and anti‐inflammatory activities. Based on our previous study, the effect of EGCG on endothelin‐1 (ET‐1)‐induced CRP production in rat vascular smooth muscle cells (VSMCs) and the possible mechanism were observed. The in vitro experiments showed that EGCG concentration‐dependently inhibited ET‐1‐stimulated expression of CRP both in protein and mRNA levels in VSMCs as determined by the immunocytochemical staining, the enzyme‐linked immunosorbent assay and the real‐time quantitative polymerase chain reaction (RT‐qPCR). The in vivo investigation with the double‐labelled immunofluorescence staining and RT‐qPCR displayed that EGCG also prevented ET‐1‐induced CRP expression in protein and mRNA levels in the aortic VSMCs of rats receiving the subchronic infusion of ET‐1. In addition, EGCG suppressed reactive oxygen species (ROS) generation evoked by ET‐1 in VSMCs as observed by the fluorescence probe. These demonstrate that EGCG may inhibit ET‐1‐stimulated generation of CRP in VSMCs so to relieve the inflammatory response and oxidative stress via blocking ROS signal, which provides new evidence for an anti‐atherosclerotic effect of EGCG.